Phase II Multicenter Study of Eftilagimod Alpha and Pembrolizumab in Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to evaluate the **objective response rate** of eftilagimod alfa (efti) in combination with pembrolizumab in patients with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). This evaluation will be conducted in two cohorts: Cohort A, where the combination therapy will be compared to pembrolizumab alone, both overall and according to stratification factors such as Combined Positive Score (CPS), and Cohort B, where the combination therapy will be assessed independently. The objective response rate is a critical measure of the efficacy of cancer treatments, indicating the proportion of patients whose cancer shrinks or disappears after treatment.
Secondary objectives include:
- Evaluating overall survival and further antitumor activity of efti combined with pembrolizumab in Cohort A, compared to pembrolizumab alone, and in Cohort B.
- Assessing the safety and tolerability of the combination therapy compared to pembrolizumab alone.
- Investigating the immunogenic properties of efti when combined with pembrolizumab.
Participants
The clinical trial involves a total of **44 participants** diagnosed with **metastatic head and neck squamous cell carcinoma (HNSCC)**. The study population includes both male and female subjects aged **18 years and older**. Participants were selected based on their willingness to provide informed consent and their compliance with the protocol. The trial does not include a vulnerable population. Participants are required to have a measurable disease as per the Response Evaluation Criteria in Solid Tumors version 1.1, and they must be PD-X naïve. The trial population is characterized by a general health status that allows for participation in a first-line palliative setting, with an **ECOG performance status** of 0-1. Lifestyle considerations such as diet and physical activity are not specified, but all subjects of reproductive potential must agree to use highly effective contraception methods. The trial does not specify any particular lifestyle habits or restrictions beyond the medical criteria outlined.
Plans and Procedures
The clinical trial is designed as a **randomized**, open-label, Phase II study to evaluate the efficacy of a combination therapy involving **eftilagimod alfa** and **pembrolizumab** for the treatment of unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). The trial aims to assess the **objective response rate** of the combination therapy compared to pembrolizumab alone, with additional evaluations based on stratification factors. The study is expected to run from August 2021 to February 2025, with a maximum treatment period of 24 months for participants.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as measurable disease, laboratory values, and biomarker availability. Following randomization, participants will receive either the combination therapy or pembrolizumab alone. Regular follow-up visits will be conducted to monitor treatment response, safety, and any adverse events. The end-of-study visit will conclude the participant's involvement, assessing the final treatment outcomes and any long-term effects.
The expected length of participant involvement is up to 24 months, contingent upon individual response and tolerance to the treatment. Conditions that may lead to early termination from the study include significant adverse events, disease progression, or withdrawal of consent. The trial will adhere to rigorous safety and efficacy assessments, including the monitoring of **adverse events** and the occurrence of anti-eftilagimod-specific antibodies. The primary endpoint is the objective response rate according to RECIST 1.1, with secondary endpoints including overall survival, progression-free survival, and quality of life assessments.
Treatment
The clinical trial involves the administration of **IMP321**, a **solution for injection** containing the active substance **eftilagimod alfa**. This investigational medicinal product is provided by IMMUTEP S.A.S. and is classified as a protein of other origin. The pharmaceutical form is a solution for injection, and it is administered via **subcutaneous use**. The maximum daily dose is 30 mg, with a total maximum dose of 1200 mg over a treatment period of 24 weeks. The dosing schedule and participant compliance are monitored to ensure adherence to the protocol.
In addition to IMP321, the trial also includes the administration of **KEYTRUDA 25 mg/mL concentrate for solution for infusion**, which contains the active substance **pembrolizumab**. This product is manufactured by MERCK SHARP & DOHME B.V. and is also a protein of other origin. The pharmaceutical form is a solution for infusion, administered via **intravenous use**. The maximum daily dose for pembrolizumab is 400 mg, with a total maximum dose of 7200 mg over a 24-week treatment period. The administration of pembrolizumab is conducted in accordance with the study protocol, and participant compliance is closely monitored.
The trial aims to evaluate the objective response rate of eftilagimod alfa in combination with pembrolizumab in subjects with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck. The study design includes a comparison of the combination therapy to pembrolizumab alone, with stratification factors considered in the analysis. No additional non-experimental treatments, such as standard-of-care therapy or placebo, are specified in the trial protocol.
Efficacy
Efficacy in this clinical trial will be assessed using several key endpoints. The primary endpoint is the **Objective Response Rate (ORR)**, evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary endpoints include overall survival (OS), ORR according to immune-related RECIST (iRECIST), time to and duration of responses as per iRECIST and RECIST 1.1, disease control rate according to iRECIST and RECIST 1.1, and progression-free survival (PFS) according to iRECIST and RECIST 1.1. Additionally, the occurrence of anti-efti-specific antibodies, safety profile, and quality of life using EORTC QLQ-H&N43 and EORTC QLQ-30 will be evaluated.
The trial will involve the administration of eftilagimod alpha (IMP321) in combination with pembrolizumab for the first-line treatment of subjects with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). Efficacy assessments will be conducted at specified intervals throughout the trial, with the primary endpoint being measured at the end of the treatment period. The trial is designed to compare the combination therapy to pembrolizumab alone, with stratification factors such as Combined Positive Score (CPS) being considered in the analysis. The trial is expected to conclude by February 2025.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Willing to give written informed consent and to comply with the protocol.
- Histologically- or cytologically confirmed recurrent disease not amenable to curative treatment with local or systemic therapy, or metastatic (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx that is considered incurable by local therapies and to be treated in the first line palliative setting and who are PD-X naïve.
- Availability of tissue for PD-L1 biomarker analysis from a core or excisional biopsy (fine needle aspirate is not sufficient). A newly obtained biopsy (within 90 days prior to start of trial treatment) is preferred but an archival sample is acceptable.
- Availability of PD-L1 biomarker result by using the FDA approved Dako standardized diagnostic test (PD-L1 IHC 22C3 pharmDx)
- Availability of tissue for testing of human papillomavirus (HPV) status for oropharyngeal carcinoma (p16 expression testing). Note: If HPV status was previously tested using this method and result isavailable, no additional testing in central laboratory is required for this trial.
- Female or male ≥18 years of age on the day of signing the informed consent.
- All female subjects of childbearing potential must have a negative highly sensitive pregnancy test at screening (within 72 hours prior to cycle 1 day 1); all subjects of reproductive potential must agree to use highly effective method for contraception from trial entry until at least 4 months after the last administration of any trial treatment
- A woman must either be, a) not of childbearing potential: postmenopausal (≥ 60 years of age, or < 60 years of age and amenorrhoeic for 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression with follicle-stimulating hormone (FSH) above 40 U/L and estradiol below 30ng/L, or if taking tamoxifen or toremifene, and age < 60 years, then FSH and estradiol in the postmenopausal range), permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy), or otherwise incapable of pregnancy b) of childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies: e.g., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; male partner sterilization (the vasectomized partner should be the sole partner for that subject).
- ECOG performance status 0-1.
- Evidence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1. Lesions situated in a previously irradiated area is considered measurable if progression has been demonstrated in such lesions.
- Subjects who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization. Note: Subjects should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of trial intervention.Hepatitis B screening test are not required unless: a) known history of HBV infection. b) mandated by local health authority.
- Subjects with history of HCV infection are eligible if HCV viral load is undetectable at screening.
- HIV infected subjects must be on anti-retroviral therapy and have a well-controlled HIV infection/disease defined as: a) Subjects on ART must have a CD4+ T-cell count >350 cells/mm3 at time of screening b) Subjects on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening c) Subjects on ART must have been on stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to cycle 1 day 1 Note: no HIV testing is required unless mandated by local health authority.
- Laboratory criteria: a) Absolute neutrophil count > 1.5 x 10^9/L b) Platelet count ≥ 100 x 10^9/L c) Hemoglobin ≥ 9 g/dL or 5.58 mmol/L d) Serum creatinine ≤ 1.5 × ULN, or if > 1.5 ULN with a clearance of ≥ 50 mL/min acc. to Gault-Cockcroft formula e) Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 x ULN Note: subjects with known Gilbert's syndrome can be enrolled. f) AST (=SGOT) and ALT (=SGPT) ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present. g) International normalized ratio (INR) or prothrombin time (PT) ≤1.5 ×ULN unless subject is receiving anticoagulant therapy as long as PT or activated partial thromboplastin time (aPTT) is within therapeutic range of intended use of anticoagulants
Exclusion Criteria
- Disease is suitable for local therapy administered with curative intent
- Previously treated with ≥ 1 systemic regimen for recurrent and/or metastatic disease (with the exception of systemic therapy completed >6 months prior if given as part of multimodal treatment for locally or locoregionally advanced disease)
- Histologically or cytologically confirmed head and neck carcinoma of any other primary anatomic location in the head and neck not specified in the inclusion criteria including subjects with HNSCC of unknown primary, squamous cell carcinoma originating from skin, or nonsquamous histologies (e.g. nasopharynx, salivary gland or mucosal melanoma)
- Has progressive disease (PD) within 6 months of completion of curatively intended systemic treatment for locally or locoregionally advanced HNSCC, or requires chemotherapy based therapeutic regimen due to e.g., rapidly progressing disease or need of aggressive symptom control.
- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic Tlymphocyte-associated antigen-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co- stimulation or checkpoint pathways)
- No PD-L1 expression result available by cycle 1 day 1.
- Prior anti-LAG-3 therapy
- Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
- Prior targeted small molecule therapy, or radiation therapy within 2 weeks prior to cycle 1 day 1.
- Has received prior chemotherapy, anti-cancer monoclonal antibody, major surgery, another systemic cancer therapy or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to cycle 1 day 1.
- Known active central nervous system metastasis and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable: i.e. without evidence of progression documented by repeat imaging performed after therapy completed for CNS metastasis and with at least 4 weeks difference, clinically stable and without requirement for steroid treatment for at least 14 days prior to cycle 1 day 1.
- Pregnant, breastfeeding or expecting to conceive or father children within the projected duration of the trial starting with screening visit. A woman of child-bearing potential who has a positive serum pregnancy test (within 72 hours) prior to cycle 1 day 1.
- Serious intercurrent infection within 4 weeks prior to cycle 1 day 1 or active acute or chronic infection.
- Evidence of severe or uncontrolled cardiac disease within 6 months prior to first dose of trial treatment including: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE version 5.0 Grade ≥ 2, atrial fibrillation > grade 2 not controlled by a pacemaker, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (NYHA III-IV), cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
- Has interstitial lung disease or history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form ofsystemic treatment and is allowed.
- HIV-infected subjects with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
- Has a life-threatening illness unrelated to cancer.
- Has had an allogenic tissue/solid organ transplant.
- Has previous malignancies within the last three years other than described in inclusion criterion 2,except curatively treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, ductal carcinoma in situ of the breast, or in situ carcinoma of the cervix.
- Receives continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days prior to cycle 1 day 1. Inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalents are permitted in the absence of active auto-immune disease.
- Has a hypersensitivity to efti and/or pembrolizumab and/or any of its excipients.
- Live vaccine within 30 days of planned cycle 1 day 1.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
- Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the trial.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Belgium | Not Recruiting | 02 Aug 2021 | 14 |
Denmark | Not Recruiting | 02 Aug 2021 | 24 |
Germany | Not Recruiting | 02 Aug 2021 | 24 |
Romania | Not Recruiting | 02 Aug 2021 | 10 |
Spain | Not Recruiting | 02 Aug 2021 | 55 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
KEYTRUDA 25 mg/mL concentrate for solution for infusion | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | INTRAVENOUS USE | 400 | 24 | PRD4323105 |
IMP321 | Test | SOLUTION FOR INJECTION | SUBCUTANEOUS USE | 30 | 24 | PRD3124166 |





